Framework for PET/CT

Medical imaging studies can be divided into structural vs. functional modalities, with PET imaging being a common functional modality used in daily practice. PET imaging involves introducing positron-emitting radiotracers into the body and acquiring three-dimensional image maps of their distribution, which can help diagnose various conditions by highlighting abnormal metabolic processes. FDG-PET/CT imaging is particularly useful in oncology for detecting abnormal glucose uptake associated with cancer, although its effectiveness can vary across different cancer types and it may produce false positives or negatives due to various physiological and pathological factors. Download PDF: https://drive.google.com/file/d/1zaUY... Chapters: 00:00 - Introduction 00:59 - The Science behind PET Imaging 06:22 - The Clinical Process 12:43 - Applications in Neurology 13:30 - Applications in Cardiology 14:23 - Applications in Oncology 15:07 - FDG-PET & Brain Cancer 15:49 - FDG-PET & Bladder Cancer 16:17 - FDG-PET & Breast Cancer 16:50 - FDG-PET & Colorectal Cancer 17:48 - FDG-PET & Esophageal Cancer 18:56 - FDG-PET & Head/Neck Cancer 19:31 - FDG-PET & Kidney Cancer 20:05 - FDG-PET & Lung Cancer 20:33 - FDG-PET & Lymphoma 21:49 - FDG-PET & Melanoma 22:18 - FDG-PET & Ovarian Cancer 22:57 - FDG-PET & Cervical Cancer 23:28 - FDG-PET & Prostate/Testicular Cancer 23:46 - Non-FDG Radiotracers in Oncology 26:18 - False Positives in FDG-PET Imaging 27:02 - False Negatives in FDG-PET Imaging 27:44 - Normal Tissues with High FDG Uptake